Chimerix’s proprietary technology has given rise to brincidofovir (Brinci, BCV, CMX001), a clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. Brincidofovir has shown broad-spectrum in-vitro activity against all five families of DNA viruses that affect humans, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex viruses.
Chimerix is currently enrolling SUPPRESS, a Phase 3 study of brincidofovir for the prevention of cytomegalovirus infection in hematopoietic cell transplants (HCT ) recipients, also known as bone marrow transplants. The SUPPRESS data, if positive, would be used to support the Company’s initial regulatory submission to the FDA for Accelerated Approval. In addition, Chimerix is enrolling the pilot portion of a Phase 3 study of brincidofovir for treatment of life–threatening disseminated adenovirus infection. Chimerix is working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure to treat smallpox due to a threat of bioterror or accidental release. Brincidofovir has received Fast Track designation from the FDA for CMV, AdV, and smallpox.